Skip to main content
Fig. 4 | Respiratory Research

Fig. 4

From: Navafenterol (AZD8871) in healthy volunteers: safety, tolerability and pharmacokinetics of multiple ascending doses of this novel inhaled, long-acting, dual-pharmacology bronchodilator, in two phase I, randomised, single-blind, placebo-controlled studies

Fig. 4

Mean change from baseline in heart rate over time at day 16 (safety population) in (a) study A and (b) study B. aexcept for navafenterol 600 μg at 12 h post dose on day 16, n = 5. bpm = beats per minute; SD = standard deviation

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us